Supported by Cure Parkinson’s, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson’s.
The German biotech company ‘MODAG’ have announced that they have completed the first part (phase 1) of their clinical trial of a new Parkinson’s drug. This new drug, called “Anle138b”, is a therapy that enters the brain and targets the protein alpha-synuclein. In Parkinson’s, alpha-synuclein starts to mis-fold and clump together and it is believed that in this state alpha-synuclein becomes toxic and is a contributory factor in the progressive loss of structure or function of brain cells (neurons), that is observed in Parkinson’s.
Anle138b is a new and experimental drug that it is believed prevents alpha-synuclein from clumping together and also helps to unfold and separate already formed clumps of alpha-synuclein. Cure Parkinson’s has previously funded pre-clinical research of Anle138b in models of Parkinson’s which was conducted at the University of Cambridge by Professor Maria Spillantini.
Cure Parkinson’s is now supporting MODAG in setting up a clinical trial to test Anle138b in a cohort of individuals with Parkinson’s.
We are delighted to be working closely with Modag to support them in their future plans for the benefit of people with Parkinson’s
Helen Matthews, Deputy CEO, Cure Parkinson’s.